EXONHIT News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

13.01.14	Diaxonhit Enters into a Distribution Agreement with SAMSUNG " Health Medical Equipment " Division for Commercialization of Point of Care Diagnostic Tests (Businesswire)
16.10.13	Diaxonhit Enters into Exclusive Partnership Agreement with Japanese Tosoh Group for Marketing Immunoassay Instruments (Businesswire)
26.09.13	Diaxonhit Strengthens Its Offering in the Field of Quality Control for Clinical Laboratories (Businesswire)
17.09.13	Diaxonhit: Half-Year 2013 Results (Businesswire)
03.09.13	Diaxonhit Signs a Research Service Agreement with Boehringer Ingelheim for the Discovery of Novel Epitope Targets in Oncology (Businesswire)
25.07.13	Diaxonhit Mid-Year Revenues Increase to €15,9 Million (Businesswire)
06.11.12	Exonhit announces the upcoming acquisition of InGen BioSciences, the leading independent distributor of in-vitro diagnostics in the French market (1) (Businesswire)
11.09.12	Exonhit – Half-Year 2012 Results (Businesswire)
16.07.12	Alzheimer's disease: patient enrollment completed ahead of plan in Exonhit’s studies on AclarusDx® (Businesswire)
05.06.12	Exonhit Receives € 1.93 Million from OSEO within the Personalized Medicine TEDAC Project in Cancer (Businesswire)
22.03.12	EXONHIT SA Reports 2011 Results (Businesswire)
05.03.12	Exonhit is Beneficiary of a Grant from the European Union within the Responsify Consortium (Businesswire)
12.12.11	Exonhit: AclarusDx®: Launch of Observational Study in France (Businesswire)
29.03.11	ExonHit Announces Successful Completion of the First Phase of EHT Dx14 Ongoing Clinical Validation (Businesswire)
15.03.11	ExonHit Therapeutics reports 2010 results (Businesswire)
02.11.09	ExonHit Will Participate in the MAPT Study for the Prevention of Cognitive Decline in Old People (Businesswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’406.50	1.48 %	K V
Swiss Life Hldg	764.20	1.16 %	K V
Kuehne+Nagel Int	203.80	1.14 %	K V
Logitech Intl	91.02	0.91 %	K V
ABB	50.08	0.81 %	K V
Nestle	77.36	-0.18 %	K V
Swisscom	526.00	-0.19 %	K V
UBS Group	30.31	-0.36 %	K V
Givaudan	3’828.00	-0.57 %	K V
Alcon	81.70	-0.73 %	K V